Chemotherapy is associated with faster abdominal aortic aneurysm growth in patients with concomitant cancer in a multicenter cohort.

Authors

Harue Santiago Kumakura, Andressa Cristina Sposato Louzada, Glauco Fernandes Saes, Guilherme Yazbek, Nelson De Luccia, Pedro Puech-Leão, Nelson Wolosker, Antonio Eduardo Zerati

Published in

Clinics (Sao Paulo, Brazil). Volume 81. Pages 101099. Sep 06, 2026. Epub Sep 06, 2026.

Abstract

To investigate the prevalence of synchronous Abdominal Aortic Aneurysm (AAA) and malignancy and the impact of different cancer treatments on the natural history of aortic aneurysms, focusing on its growth and risk of rupture.
Retrospective multicenter observational study.
Imaging scans were examined to select patients with abdominal aortic aneurysms. Aortic diameters, aortic rupture, demographic and clinical data from patients with abdominal aortic aneurysms with or without cancer (controls) treated at four medical centers in Brazil were retrospectively analyzed.
27,455 abdominal scans were screened, resulting in 297 patients with AAA being included. Of these patients, 220 had concomitant cancer. The prevalence of AAA and cancer was 2.4%. A further 73 patients with AAA but no cancer were recruited from an outpatient cohort to also join the control group of 77 patients, resulting in 150. No aortic rupture was observed. In multivariable analysis, larger baseline aortic diameter (p < 0.001) and exposure to alkylating agents (p = 0.023), antimetabolites (p = 0.023), and topoisomerase inhibitors (p = 0.003) were independently associated with increased AAA growth rates. Neither cancer diagnosis nor radiotherapy exposure was significantly associated with AAA growth.
2.4% of cancer patients had a concomitant AAA. Aneurysm growth rates were significantly influenced by the initial aortic diameter and by treatment with three classes of chemotherapy drugs: alkylating agents, antimetabolites and topoisomerase inhibitors.

PMID:
42702108
Bibliographic data and abstract were imported from PubMed on 07 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.